Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
Dr. Reddy’s Laboratories Limited reports that the U.S. Securities and Exchange Commission has concluded its investigation into earlier anonymous allegations of improper payments to healthcare professionals in Ukraine and other markets. The SEC’s letter dated February 23, 2026 states it does not intend to recommend any enforcement action against the company at this time.
The company notes that the SEC’s communication, issued under Securities Act Release No. 5310, should not be read as an exoneration or a guarantee that no action will ever result, but it does indicate that the current investigation is being closed without an enforcement recommendation.
Dr. Reddy’s Laboratories has agreed to acquire the Indian trademarks and related assets of hormone replacement therapy brands Progynova® and Cyclo‑Progynova® from Mercury Pharma Group Limited for USD 32.15 million.
Progynova®, an estradiol valerate therapy, is described as the #1 brand in the estradiol represented pharmaceutical market in India and recorded sales of INR 100 crore as per IQVIA MAT December 2025. Cyclo‑Progynova® combines estradiol valerate and norgestrel for estrogen deficiency symptoms treatment.
The deal is not a related‑party transaction and is intended to strengthen Dr. Reddy’s gynecology portfolio in India and mark a strategic entry into the hormone replacement therapy segment.
Dr. Reddy’s Laboratories Limited has allotted 12,665 equity shares of Re.1 each on February 17, 2026 to eligible employees following the exercise of stock options. These options were granted under the Dr. Reddy’s Employees Stock Options Scheme, 2002 and the Employees ADR Stock Option Scheme, 2007.
The shares were exercised at prices ranging from Re.1 to Rs. 735.80 per share, and the new shares rank pari passu with existing equity shares. After this allotment, total issued shares are 83,46,44,020 and total issued share capital is Rs. 83,46,44,020, with paid-up capital of 83,46,43,020 equity shares of Re.1 each.
Dr. Reddy’s Laboratories Limited has notified exchanges that its management will participate in an investor conference organized by Kotak Institutional Equities. The meetings are scheduled in Mumbai on 23 February 2026, will be held in person, and structured as group meets from 09:00 to 17:00 IST. The company notes the schedule may change if required by either the investors or the company.
Dr. Reddy’s Laboratories Limited has filed a Form 6-K to report that Mr. Sushrut Kulkarni, Global Head of IPDO and Senior Management Personnel, has resigned. He will cease employment and senior management responsibilities effective from the close of business on May 8, 2026, as he plans to explore opportunities outside the company.
The company states that the disclosure is made under Regulation 30 of the SEBI Listing Regulations, with required details provided in an annexure. In his resignation letter, Mr. Kulkarni undertakes to support the company during his notice period and ensure a smooth handover of responsibilities.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its schedule for an upcoming investor interaction. The company’s management plans to participate in a Nuvama-organized investor conference in Mumbai on 9 February 2026, holding in-person group meetings from 09:00 to 17:00 IST. The company notes that this schedule may change if required by either the investors or the company.
Dr. Reddy’s Laboratories reported Q3 FY26 results showing modest overall growth but pressure on earnings. Revenue grew 4.4%, driven by double-digit gains in base businesses excluding Lenalidomide and supported by favourable foreign exchange.
Reported EBITDA margin was 23.5%, including a one-time provision from changes in Indian Labour Codes; excluding this, margin was 24.8%. Profit before tax was ₹ 1,543 crores, with a 17.7% PBT margin, or 19% without the labour provision. Profit after tax attributable to equity holders was ₹ 1,210 crores, down 14% year-over-year and 16% sequentially, at 13.9% of revenues.
India revenue reached ₹ 1,603 crores, up 19% year-over-year, supported by innovation brands, new launches, price increases, higher volumes and the acquired Stugeron portfolio. The company ended the quarter with a net cash surplus of ₹ 3,069 crores and generated free cash flow of ₹ 374 crores, while preparing for Semaglutide launches and advancing biosimilar programs such as Abatacept and Denosumab.
Dr. Reddy’s Laboratories Limited reports that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories LLC in Russia, has received a tax audit decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia dated January 23, 2026. The authority reclassified certain marketing services as taxable, levying Value Added Tax (VAT) and quantifying a penalty of Rub million 20.09, stated as INR 24.50 million.
The company states that, based on its evaluation, this tax decision has no material impact on its financials, operations, or other activities. Dr. Reddy’s plans to evaluate filing a reply with the Russian tax authority in response to the decision and is providing this update to stock exchanges in India and the New York Stock Exchange.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share an audio recording of its earnings call for the quarter ended December 31, 2025. The call was conducted on January 21, 2026, and the company has provided a web link to the full audio recording for investors and exchanges.
The notice has been sent to the National Stock Exchange of India, BSE, New York Stock Exchange, and NSE IFSC, underscoring that this is a formal communication of the recorded earnings discussion for regulatory and investor information purposes.
Dr. Reddy’s Laboratories Limited filed a Form 6-K as a foreign private issuer, providing an intimation dated January 21, 2026. The company has circulated a presentation on its unaudited financial results for the quarter ended December 31, 2025 to the National Stock Exchange of India, BSE, the New York Stock Exchange, and NSE IFSC.
The filing itself does not reproduce the financial figures, but formally records that these quarterly unaudited results have been prepared and shared with the stock exchanges for information and record purposes.